Efficacy of the MEK1/2 inhibitor trametinib in combination with clinically-investigated γ-secretase inhibitors in rhabdomyosarcoma
M. Cleary, D. S. Hawkins, C. Keller
This study tests the efficacy of trametinib and gamma-secretase inhibitors in RMS cell lines, finding no significant effect on cell viability when combined.
bioRxiv · Apr 29, 2019 · PreprintCancer Biology